Capiton Ag
Capiton AG describes itself as an owner-managed, mid-market private equity investor providing capital, market access, change expertise, and partnership support to medium-sized companies. It states that it invests in profitable companies in the DACH region, typically using EUR 20 million to EUR 60 million of its own funds per investment and acquiring majority or minority stakes.
What stands out about Capiton Ag
Capiton AG publicly targets profitable medium-sized companies with annual revenue between EUR 50 million and EUR 300 million, principally in High-Tech Industrials and Healthcare & Life Sciences, with a clear focus on the German-speaking DACH region. Its stated transaction situations include succession, management buy-outs or buy-ins, growth, buy-and-build, carve-outs, and continuation funds.[1][2][3][8]
What does Capiton Ag invest in?
Capiton AG describes itself as an owner-managed, mid-market private equity investor that provides capital, market access, change expertise, and partnership support to medium-sized companies.
The official imprint identifies Capiton AG as headquartered in Berlin, Germany, and registered with the Charlottenburg Local Court under commercial-register number HRB 76400.[1][2]
Capiton invests in profitable medium-sized companies in the DACH region and acquires both majority and minority stakes. It typically invests EUR 20 million to EUR 60 million of its own funds per investment.
Capiton states that it considers succession, management buy-out or buy-in, growth, buy-and-build, carve-out, and continuation-fund situations as reasons for investment.[3]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
What should a business owner evaluate before considering a transaction with Capiton Ag?
An owner evaluating Capiton can compare the company’s stated DACH focus, revenue parameters, typical own-fund investment range, majority and minority investment approach, and identified transaction situations with the proposed transaction.
Ownership percentage, governance rights, valuation methodology, financing assumptions, rollover expectations, investment horizon, exit approach, operating support, add-on plans, and transaction expenses should be confirmed directly for the specific fund or co-investor structure. The cited official news archive does not state complete ownership percentages, valuation or financing terms, or transaction consideration amounts for the listed announcements, and Capiton’s official strategy page does not publish a universal holding-period range.[3][5][8]
Which Capiton fund or continuation vehicle would invest, and what is the remaining fund life
What portion of consideration would existing owners or management be expected to roll over
What companies does Capiton Ag target?
Capiton states that it focuses on profitable medium-sized companies with annual revenues between EUR 50 million and EUR 300 million. Its stated typical own-fund investment range is EUR 20 million to EUR 60 million per investment.[3]
Capiton’s stated focus sectors are High-Tech Industrials and Healthcare & Life Sciences.[3]
Capiton states that it has a clear focus on the German-speaking DACH region.[2]
Capiton identifies buy-and-build as one of the transaction situations it considers. Its official investor-relations page also describes a co-investment model for larger transactions and investments with high capital requirements.
The cited materials establish buy-and-build as a transaction situation but do not establish a specific add-on framework or threshold.[3][5]
Capiton’s official portfolio identifies current holdings including Addvance Group, AEMtec GmbH, AlphaPet Ventures & Healthfood24, Asyril SA, Axxence Group, CEDES AG, Dec Group, EVP/Vitafy, HCD Healthcare & Diagnostics, KD Pharma Group, MIP, Raith GmbH, Solvis GmbH, SAPV Care, and Wundex Group.[4]
Capiton announced on July 28, 2026 that Capiton Quantum successfully sold AEMtec Group to Micross Components, Inc. The announcement states that AEMtec had been a Capiton investment since 2018 and was transferred to the Capiton Quantum continuation vehicle in 2023.
Capiton announced on March 3, 2026 that Capiton VI, together with LP co-investors, acquired a majority stake in SAPV Care GmbH, a specialized outpatient palliative-care provider in Germany.
The official news archive also lists AlphaPet Ventures’ acquisition of Tierliebhaber on April 2, 2026, AlphaPet Ventures’ acquisition of Cpro Food on April 1, 2026, and Capiton V’s sale of Anovis to x-tention Group on March 31, 2026.[6][7][8]
What is not clear from Capiton Ag's public investment criteria?
Capiton’s official news archive lists dated transaction announcements but does not state transaction consideration amounts, enterprise values, equity checks, financing terms, or complete ownership percentages for the listed announcements.
Capiton’s official strategy page states the investment criteria and transaction situations but does not publish a universal expected investment holding-period range.[3][8]
Questions to ask when evaluating Capiton Ag as a buyer or investment partner
Which Capiton fund or continuation vehicle would invest, and what is the remaining fund life?
What ownership percentage and governance rights would be sought in the proposed transaction?
What portion of consideration would existing owners or management be expected to roll over?
How would Capiton define the valuation range and financing assumptions for the target company?
The cited official Capiton news archive does not state enterprise values, equity checks, financing terms, or transaction consideration amounts for the listed announcements.[8]
What is the expected investment horizon and exit approach for this transaction?
What add-on, internationalisation, or buy-and-build plan is contemplated?
What transaction fees, monitoring fees, break fees, or other deal expenses would apply?
The cited official news archive’s listed announcements do not provide financing and consideration details; fee terms should be requested directly.[8]
Sources & research notes
- Official website / firm overview
- Services / capabilities
- Investment strategy
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Structure / regulatory context
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.